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Lower than ideal COVID-19 vaccination rates are problematic nationally. As of
March 4th, 2022 65% of eligible Americans were fully vaccinated (CDC, 2022). South
Carolina fell below the national rate with only 57% of eligible South Carolinians were
fully vaccinated at the same time period (SCDHEC, 2022). Both rates are below the
national goal that was set for nation of 70% of eligible Americans being fully vaccinated
by July 4th, 2021. This project aimed at exploring the motivation of individuals who
would be considered late adopters. It was found that motivation to become vaccinated
was varied and personal. The conclusion was that vaccination communication should be
culturally appropriate and personalized for the best outcome.
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Exploring Late Adopter Motivation: A Corona Virus (COVID-19) Vaccine Quality
Improvement Project
As of March 4th, 2022, the Centers for Disease Control and Prevention
(CDC) (2022) reported over 78 million cases of SARS-COV-2, also known as: COVID,
COVID-19, and the Corona virus in the United States since the beginning of the COVID19 pandemic in March of 2020. Of those cases, 952,223 have resulted in death. The
South Carolina Department of Health and Environmental Control (SCDHEC) (2022)
reported 1,145,180 confirmed cases and 14,420 deaths in the same period in the state of
South Carolina.
Long-term effects of COVID-19 infection, also known as long COVID, can be
devastating (CDC, 2021). Symptoms of long COVID-19 include, but are not limited to,
shortness of breath, chest pain, joint or muscle pain, neurological changes, and many
other debilitating symptoms. Multi-organ effects of COVID-19 can affect any body
system and even trigger autoimmune symptoms. Immunization against SARS-Cov-2,
with one of the three vaccines that are approved for emergency use, is the next step to
reduce the effects of COVID-19 on our communities.
The SARS-Cov-2 vaccine has been available since December 2020. The three
vaccines available include two mRNA vaccines, one produced by Pfizer-BioNTech and
another by Moderna and one viral vector vaccine produced by Johnson & Johnson (CDC,
2022). Due to the increased efficacy and lower risk of serious side effects the Centers for
Disease Control and Prevention (2022) recommends that vaccination with one of the two
mRNA vaccines is preferable to the Johnson & Johnson viral vector vaccine. The CDC
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(2022) does note that administering the Johnson & Johnson vaccine is preferable to not
administering a vaccine.
COVID-19 vaccines have made a substantial impact in mortality and
hospitalizations due to COVID-19 (Vilches, et al., 2022). Vilches, et al. (2022) noted that
between December 12th, 2020, to June 30th, 2021, the COVID-19 vaccine prevented an
estimated 240,797 deaths and an estimated 1,133,617 hospitalizations in the United
States. Vilches, et al. (2022) also noted that vaccination efforts also were responsible for
lessening the impact of an Alpha variant wave that was projected to occur in April 2021.
Translating this model to South Carolina would be difficult due to the below average
vaccination uptake in the state.
As of March 4th, 2022, 67% of all eligible South Carolinians over the age of
twelve have received at least one vaccine dose and only 57% in the same age group are
fully vaccinated (SCDHEC, 2022). This is below the national vaccination rate of 76% of
the U.S. population had received at least one dose of a COVID-19 vaccine and 65% of
the total U.S. population was fully vaccinated for the same time period (CDC, 2022). The
national goal to have seventy percent of US adults fully vaccinated by July 4th, 2021, was
set by the Biden administration. South Carolina’s vaccination rate fell short of that goal.
In the beginning of August 2021 only 52% of South Carolinians had at least one dose of
vaccine (SCDHEC, 2021). This is below the U.S. vaccination rate of 55% of eligible
Americans had received at least one does of an approved COVID-19 vaccine (CDC,
2021). According to SCDHEC’s Vaccine Finder website, vaccination sites were well
distributed across the state and vaccines were available in every area of the state
(SCDHEC, 2021). Vaccine hesitancy and apathy are associated with low vaccination
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rates (Wood & Schulman, 2021). To increase the vaccination rates, it was important to
first understand the concerns that were keeping people from getting the vaccine and what
factors changed their decision(s).
This is not a unique problem to South Carolina. Nationally and internationally,
there is a trend of vaccine hesitancy or apathy (Wood & Schulman, 2021). Wood and
Schulman (2021) noted that much of the current research did not include responses that
would indicate apathy and limited to responses that more likely described hesitancy.
Experts note that the origin of this behavior is multifactorial (Rosenbaum, 2021).
Rosenbaum (2021) noted that some individuals receive their information from scientific
experts while others utilize their own experiences or heard truths from their social
networks. This is not a new phenomenon. This behavior dates to the second half of the
19th century, when the first mandated vaccines were implemented (Tibbetts, 2021). Given
the complexity of vaccine resistance, it is no longer sufficient to encourage public
understanding of science; science must understand the public (Rosenbaum, 2021).
This quality improvement project is aimed at gathering data to determine what
caused the late adopters to elect to receive the vaccine. A better understanding of what
information was needed to ease the minds of the hesitant and the apathetic was needed to
adjust education and marketing tactics. Nurses at a vaccine site surveyed vaccine
recipients about their motivation to become vaccinated. Responses were evaluated for
trends to determine the focus of marketing and educational campaigns to increase
vaccination rates. Approaching the late adopters and understanding their hesitancy
provided insight into how the decision was made and how to improve education and
communication that targeted specific concerns.
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Literature Review
Addressing lower than ideal SARS-Cov-2 vaccination rates, based on a national
goal of seventy percent of eligible individuals being vaccinated, will need to be
approached from various angles. According to Wood and Schulman (2021) hesitancy
alone is not responsible for low vaccination rates. Vaccine apathy also plays a role in
vaccination rates (Wood et al., 2021). Vaccine apathy refers to a disinterest in the vaccine
while hesitancy describes an anxiety around safety, adverse events, or political motives
(Wood et al., 2021).
Vaccine hesitancy is rooted in anxiety around adverse effects, reactions, longterm health risks, or historical medical practices that have resulted in a level of mistrust in
various communities (Di Gennaro et al., 2021; Rosenbaum, 2021; Thompson et al., 2021;
Wood et al., 2021; & Wood & Shulman, 2021). Thompson et al. (2021) noted that
medical mistrust is prevalent in the Black community due to historical racist exploitation
such as the Tuskegee experiment. These researchers also found that forty-five percent of
surveyed individuals that identify as black reported 1 in 6 encounters with health care
professionals were negative. Individuals who are vaccine hesitant are high-involvement
decision makers (Wood et al., 2021). These individuals seek out information and actively
look for information that supports or disproves their current stance (Wood et al., 2021).
Much of the available research has focused on the views of the unvaccinated
population(s), likely to understand where to focus education and marketing efforts.
Multiple international studies have noted a range of acceptance of the SARS-Cov-2
vaccine from 49.7% to 61.7% of respondents indicating either being vaccinated or
intending to receive the SARS-Cov-2 vaccine (Akarsu et al., 2020; Al-Metwali et al.,
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2021; Danabal et al., 2021; Fisher et al., 2020; & Guidry et al., 2021). These studies
noted factors such as social norms, income, race or ethnicity, education level, income,
previous influenza vaccination, exposure or belief in misinformation, and trust in science
or the government that could all impact an individual’s decision to receive a SARS-Cov2 vaccine (Akarsu et al., 2020; Al-Metwali et al., 2021; Danabal et al., 2021; Fisher et al.,
2020; & Guidry et al., 2021).
Several reasons for vaccine hesitancy or apathy were identified from the existing
literature. Concerns about the safety, rapid development, side effects, efficacy, testing
procedures used in development, and storage conditions of the vaccine were reported by
those respondents who stated they would not receive, or were hesitant to receive the
vaccine (Akarsu et al., 2021; Al-Metwali et al., 2021; Danabal et al., 2021; Fisher et al.,
2020; Funk & Tyson, 2021; Graupensperger et al., 2021; & Guidry et al., 2021). Funk
and Tyson (2021) also found that some individuals did not receive vaccines or felt like
they did not need it. It was also noted that beliefs consistent with conspiracy theories or
vaccine misinformation were reported by respondents that did not intend to receive the
SARS-Cov-2 vaccine (Akarsu et al., 2021; Al-Metwali et al., 2021; Fisher et al., 2020;
Pivetti et al., 2021). Pivetti et al. (2021) referenced Douglas et al. (2019) to define
conspiracy theories as a secret between two or more powerful actors to attempt to usurp
political or economic power, violate rights, infringe upon agreements, withhold vital
secrets, or alter institutions.
Given the wide range of reasons individuals provide to not receive the vaccine a
multifaceted approach to vaccine education and marketing is recommended (Al-Metwali
et al., 2021). Guidry et al. (2021) concluded that vaccine efforts would need to address
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misinformation in a culturally appropriate manner and be provided via various media
outlets.
Methods
Researchers use data gathered by nurses at a drive through vaccine site in the
upstate of South Carolina. Using a convenience sampling method, nurses queried patients
who presented for a Pfizer COVID-19 vaccine regarding their motivation for change.
Data collection period spanned three months - June 1, 2021, to August 31, 2021. The
timing of this survey was important to ensure that outside factors were not influencing the
decision of the vaccine recipients. It is important to note that this survey was started prior
to the U.S. FDA’s (United States Food and Drug Administration) full approval the PfizerBioNTech COVID-19 Vaccine, Comirnaty on August 23rd, 2021 (FDA, 2022). Data
collected included age, race, and a brief statement of motivation. Data was manually
recorded as each patient was seen and given to the site manager daily. The site manager
was then able to create a central electronic record of results to be reviewed. Nurses were
instructed to gather this information in a conversational manner. Vaccine recipients were
identified as 1st time recipients of the Pfizer-BioNTech COVID-19 vaccine. The nurse
would then complete the recommended CDC questionnaire to determine appropriateness
of providing vaccine. As the nurse conversed with the patient, they would ask a question
like “We are trying to determine if our organization could improve our vaccine education.
What made you decide to receive your COVID-19 vaccine today?” It was appropriate to
utilize this method to encourage conversation. This open-ended verbal question allowed
for a fully subjective response from each recipient. This method was utilized to allow
recipients to clarify any questions regarding the intent of the survey question. It allowed
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for a broader range of answers that were not limiting to the patient or misunderstood by
the patient. It was imperative that the purpose of the survey was communicated clearly to
minimize response bias, specifically social desirability bias and demand characteristics.
The data was reviewed for themes regarding vaccine adoption to determine if themes
were present that could help the vaccination site and health system leadership to improve
education and communication efforts.
Results
Forty-six vaccine recipients were surveyed with a 100% response rate. The mean
age of the respondents was 44 years old; the median age was 44 years old, and the range
was 65 years (16 years old – 81years old). The near-equal mean and median indicated
symmetrical age distribution. The reported gender distribution was 27 females (59%) and
19 males (41%). Race was self-reported by respondents; 26 (57%) identified as White, 13
(28%) as Black, and seven (15%) as Hispanic.
Table 1. Baseline Characteristics of Vaccine Recipients
Characteristics
Recipients (n=46)
No. (%)
Age Group
< 18
2(4%)
18-29
10(22%)
30-39
8(17%)
40-49
10(22%)
50-59
8(17%)
60-64
3(7%)
≥65
5(11%)
Self-Reported Gender
Female
27(59%)
Male
19(41%)
Self-Reported Race
White
26(57%)
Black
13(28%)
Hispanic
7(15%)
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Ten themes were identified from the data collected. The themes varied from
emotional, family, peer related motivations, fact-based decisions, and opportunity
including readily available vaccine or not having prior opportunity to receive the vaccine
due to competing priorities.
Chart 1. Late Adopter Motivation Theme Frequencies

Late Adopter Motivation Themes
8
7
6
5
4
3
2
1
0

Opportunity
Seven (15%) respondents reported opportunity as the reason for receiving the
COVID-19 vaccine. These responses indicated that the individual was receiving the
vaccine because of convenience, or they had not had the opportunity to receive the
vaccine until that time. The age distribution for individuals who reported opportunity as
motivation for vaccination was a mean of 39 years old, a median of 36, and a range of 50
years (16-66). Two (29%) males and five (71%) females responded with a reason that
was categorized as opportunity. The race distribution was five (71%) White respondents,
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one (14%) Black respondent, and one (14%) Hispanic respondent. A sampling of these
responses:
“I rode with my neighbor here. Thought I might as well get it.”
“I was just delivering a package here and someone asked me if I wanted to get
vaccinated.”
Family Request or Pressure
Six (13%) responses were categorized as family request or pressure. These
respondents indicated that their motivation was due to a family member’s request or
pressure. The age distribution was a mean 42 years old, a median 44 years old, and a
range of 55 years (17-72). An equal distribution of three males and three females reported
family request or pressure as their motivation. The race distribution for this theme was
three (50%) White respondents, two (33%) Black respondents, and one (17%) Hispanic
respondent. A sampling of responses:
“My grandma said that I promised her. I don’t remember promising her, but I am not
going to call my grandma a liar.”
“My family is making me get it. They won’t let me come visit them (in New York) until I
get vaccinated.”
Family Safety
The theme of family safety included six (13%) responses. These respondents
indicated that their motivation was related to protecting a family member from
contracting the COVID-19 virus. The age distribution was a mean of 42 years old, a
median 38.5 years old, and a range 52 years (23-75). Four (67%) respondents were male
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and two (33%) were female. Four (67%) respondents were White and two (33%) were
Hispanic. A sampling of responses:
“I waited until my daughter could be vaccinated, so we could get it together.”
“I want to hug my grandma.”
Travel
Six (13%) respondents indicated that travel requirements were the main source of
their motivation for receiving the first dose of the vaccine. The age distribution was a
mean 52 years old, median of 51 years old, and range 58 years. Two (33%) respondents
in this group were female and four (67%) were male. The reported race of respondents
was all equal with two respondents in each group of White, Black and Hispanic. A
sampling of responses:
“I need it to travel.”
“I travel lots and have come to the conclusion that everyone is going to have to have it.”
Public Health Measure Changes
Six (13%) responses indicated that the respondents’ motivation was due to recent
changes in public health measures, such as relaxed mask mandates. The age distribution
was a mean age of 36 years old, a median age of 32 years old, and a range of 27 years
(24-51). Four (67%) respondents were female and two (33%) were male. Four (67%)
respondents were Black, one (17%) respondent was White, and one respondent (17%)
was Hispanic. A sampling of responses:
“I work for the school system and felt like I needed to get the vaccine since they lifted the
mask mandate.”
“I work at Walmart. It is time, especially since masks are no longer required.”
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Fear of Illness
Four (9%) respondents indicated that their motivation was related to a fear of
illness. These individuals indicated that they were concerned with poor outcomes if they
were to contract COVID-19 or felt that receiving the vaccine may make them more
comfortable with going out in public. The age distribution was a mean of 52 years old, a
median of 56 years old, and a range of 23 years(36-59). Three (75%) respondents were
White and one (25%) was Black. Gender distribution was equal with two (50%) female
and two (50%) male respondents. A sampling of responses:
“I saw that all of the people dying were unvaccinated.”
“I have never been to the doctor or had any shots since I was itty bitty. But I really was
scared I might die without the shot.”
Vaccine Safety Information
Four (9%) respondents stated that they delayed receiving their vaccine until
sufficient safety data was available. The age distribution of this group was a mean age of
48 years old, a median 39 years old, and a range of 38 years (38-76). Three (75%)
respondents were female and one (25%) was male. All the respondents in this group selfidentified as White. A sampling of responses:
“I was waiting to see how others did…”
“…I followed Pfizer and did diligent homework and educated myself about the shots.”
Peer Request or Pressure
Three (7%) respondents indicated that they were receiving the vaccine due to peer
pressure or peer request. The age distribution was a mean of 52 years old, a median of 47
years old, and a range of 15 years (47-62). Two (67%) of these respondents were female
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and one (33%) was male. Two (67%) of the respondents in this group were Black and
one (33%) was White. A sampling of responses:
“Peer pressure, everyone else was doing it.”
“I just want to shut up my boss.”
Personal COVID-19 Experience
Three (7%) respondents credited their decision to receive a COVID-19 vaccine to
their personal experience while having COVID-19. The age distribution in this group was
a mean age of 39 years old, a median age of 37 years old, and a range of 23 years (2851). Two (67%) of the respondents in this group were female and one (33%) was male.
Two (67%) respondents were White and one (33%) was black. A sampling of responses:
“I want to protect the community and enhance my immunity since I have already had
COVID-19.”
“Having COVID-19 changed my mind. I don’t want to feel like that again. I have never
been so sick.”
Medical Professional Recommendation
One (2%) respondent, a 58-year-old White female stated that she waited for her
health care provider to recommend the vaccination.
Discussion
The data collected from this informal survey highlight the broad range of reasons
that individuals decided to receive their COVID-19 vaccine, particularly those who
would be considered late adopters. It is important to note that the broad messages that
were marketed to the public in the beginning of the vaccine campaign were not effective
in motivating these individuals to choose to receive the vaccine. Given the various
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themes in this small group of respondents, it is possible that the number of themes would
be much greater with a larger sample size. This small survey and its varied themes
emphasize the need for vaccine education to be individualized and multifaceted. All
marketing and educational campaigns for vaccination rate improvement need to be
multifaceted and culturally competent (Al-Metwali et al., 2021& Guidry et al., 2021).
There are limitations of this survey and it cannot be used to predict the behavior
of any population outside of the individuals surveyed. The sample size of this survey is
too small to determine statistical significance of age, gender, or race between themes. It is
important to note that no theme met the criteria of data saturation due to the continued
variance of the responses, therefore it cannot be determined that this is an exhaustive list
of themes. While providing an explanation of motives when surveying the respondents
was used to reduce the risk of response bias, it is still a potential limitation of this survey.
This type of bias would include an individual’s unwillingness to be completely honest to
please the surveyor. Individuals may have multiple motivations that would have been
evident with further evaluation.
This survey and further analysis bring forth the importance for further study on
the motivation of the late adopter. Further investigating this population will improve the
understanding of their motivations, thought processes, and the factors that affect their
decision making. These are all important tools to explore to potentially narrow the gap in
adoption of vaccines, treatments, and disease mitigating efforts not only with COVID-19
but with other health concerns. This mass vaccination effort has given researchers a large
population to study and determine if there are measures that can be taken to improve
adoption of public health campaigns in the future.
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Conclusion
All vaccination efforts should be multifaceted and culturally competent (AlMetwali et al., 2021& Guidry et al., 2021). It is important that individuals make a
vaccination decision based on their personal motivation; it is the role of the healthcare
system and provider to provide the proper information, risks, and benefits of treatment to
everyone. As noted by the results of this survey, it may not be the healthcare provider that
influences an individual to seek or accept a treatment. Family members and peers are
important to the decision making as well and the healthcare system must give everyone
the tools to provide the appropriate information. This information must be provided in a
culturally appropriate format and targeted toward those things that an individual holds as
important.
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